<DOC>
	<DOCNO>NCT02512237</DOCNO>
	<brief_summary>This 2-part , Phase 1 FIH study Phase 1a design determine maximum tolerate dose ( MTD ) /recommended Phase 2 dose ( RP2D ) subject metastatic cancer human epidermal growth factor receptor 2 ( HER2 ) test result situ hybridization ( ISH ) positive ( + ) immunohistochemistry ( IHC ) 3+ 2+ , Phase 1b design assess anticancer activity safety three expansion cohort : two different advance breast cancer expansion cohort ( namely , tumor test HER2 ISH positive IHC3+ tumor test HER2 ISH negative IHC 2+ ) , one advance gastric cancer expansion cohort ( tumor test HER2 ISH positive IHC3+ ) .</brief_summary>
	<brief_title>A Dose-escalation Study ARX788 , IV Administered Subjects With Advanced Cancers With HER2 Expression</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Life expectancy &gt; 12 week . 2 . BMI 18 32 kg/m2 3 . Subjects whose advanced cancer fail treatment whose cancer progress follow available standard therapy therapy acceptable subject . Subjects whose tumor tissue local laboratory result HER2 ISH positive IHC3+ must previously treat HER2 target therapy ( e.g . trastuzumab , country region therapy available part standard care ) , fail SOC therapy . Subjects previously treat HER2 target therapy trastuzumab adotrastuzumab emtansine eligible . 4 . Disease measurability : Phase 1a : measureable nonmeasureable disease ; Phase 1b : disease must measureable ( per RECIST v1.1 ) ( subject nonmeasureable disease eligible Phase 1b ) . 5 . Histopathologic evidence breast cancer base upon pathologist 's report . 6 . Tumor tissue local laboratory HER2 test result ( clinical pathology report ) base FDA regulatory agency approve , validate commercially available IHC ISH HER2 assay . Prescreening HER2 allow subject breast gastric cancer , applicable . Subjects types cancer must previously test HER2 status HER2 IHC ISH assay . 1 ) Phase 1a : ISH positive IHC 2+ 3+ . 2 ) Phase 1b : Cohort 1 : advanced breast cancer , ISH positive IHC 3+ ; Cohort 2 : advanced breast cancer , ISH negative IHC 2+ ; Cohort 3 : advanced gastric cancer , ISH positive IHC 3+ . 7 . Local pathology laboratory determination HER2 status accept , provide local laboratory accredit site HER2 test . In Phase 1b , local laboratory accredit time testing , adequate tumor tissue sample required central pathology laboratory HER2 testing . The tissue sample may provide 10 precut unstained slide tumor block . 8 . Eastern Cooperative Oncology Group Performance Status 0 1 . 9 . Acute toxicity prior therapy , surgery , radiotherapy must resolve Grade 0 1 per NCICTCAE v 4.03 . 10 . The last dose prior anticancer therapy must administer least 28 day prior first dose IMP . 11 . Adequate bone marrow function define absolute neutrophil count ≥1.5×109/L , platelet count ≥100.0×109/L , hemoglobin ≥9.0 g/dL . 12 . Adequate hepatic function define serum total bilirubin ≤1.5 × upper limit normal ( ULN ) , aspartate aminotransferase/alanine aminotransferase ≤2.5 × ULN ( ≤5 × ULN subject liver metastasis ) . 13 . Adequate renal function assess serum creatinine within reference lab normal limit creatinine clearance ( Chronic Kidney Disease Epidemiology [ CKDEPI ] Collaboration equation ) ≥60 mL/min . 14 . Adequate cardiac function assess cardiac troponin I within normal range ; leave ventricular ejection fraction ≥ 50 % institutional low limit normal ; cumulative anthracycline dose &lt; 360 mg/m2 doxorubicin equivalent . 15 . Willing able understand sign inform consent inform comply aspects protocol . 16 . Female subject must surgically sterile , monogamous partner surgically sterile , least 2 year postmenopausal , commits use acceptable form birth control ( define use intrauterine device , barrier method spermicide , condom , form hormonal contraceptive , abstinence ) duration study 3 month follow last dose study treatment . 17 . Male subject must sterile ( biologically surgically ) commit use reliable method birth control ( condom spermicide ) duration study . Any subject meet follow criterion exclude study : 1 . History allergic reaction component ARX788 . 2 . 2 . History seizure disorder . 3 . History unstable central nervous system ( CNS ) metastases seizure disorder related malignancy ; however , subject treat prior CNS metastasis asymptomatic may participate study long receive treatment steroid . 4 . History congestive heart failure , unstable angina pectoris , unstable atrial fibrillation , cardiac arrhythmia . 5 . Grade 2 4 peripheral neuropathy ( NCI CTCAE v 4.03 ) . 6 . Nonmanageable electrolyte imbalance include hypokalemia , hypocalcemia , hypomagnesemia ( Grade 2 great base NCI CTCAE v 4.03 ) . 7 . Any uncontrollable intercurrent illness , infection , condition could limit study compliance interfere assessment . 8 . Exposure investigational commercial anticancer agent therapy administer intention treat malignancy within 28 day first dose IMP . 9 . Significant surgical intervention within 21 day first dose IMP ongoing postoperative complication 21 day . 10 . Radiotherapy administrate less 21 day prior first dose IMP , localize palliative radiotherapy administer less 7 day prior first dose IMP , radiotherapy induce toxicity Grade 2 great base NCI CTCAE v 4.03 . 11 . Pregnancy breast feed . 12 . Refusal use effective method contraception ( see inclusion criterion detail ) . 13 . Legal incapacity/limited legal capacity provide informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HER2</keyword>
	<keyword>breast cancer</keyword>
	<keyword>ADC</keyword>
	<keyword>antibody drug conjugate</keyword>
	<keyword>elevate HER2 expression</keyword>
</DOC>